<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02520908</url>
  </required_header>
  <id_info>
    <org_study_id>NI 14018</org_study_id>
    <nct_id>NCT02520908</nct_id>
  </id_info>
  <brief_title>Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis</brief_title>
  <acronym>CUTALLO</acronym>
  <official_title>Prospective, Controlled, Multicenter Cohort Study Evaluating the Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidermotropic T-cell lymphomas (ETCL), i.e. mycosis fungoides (MF) and its leukemic variant,&#xD;
      Sézary syndrome, are the most frequent subtypes of cutaneous T-cell lymphomas. MF typically&#xD;
      runs an indolent course in its early stages. By contrast, advanced-stage ETCLs share a very&#xD;
      bad prognosis: Patients usually show early relapses after chemotherapy, prolonged complete&#xD;
      remissions exceptionally occur and quality of life is severely affected. Several publications&#xD;
      have reported durable responses following allogeneic hematopoietic stem cell transplantation&#xD;
      (HSCT) in advanced-stage ETCLs. This study aims to investigate the role of allogeneic HSCT in&#xD;
      treating advanced-stage ETCLs. An observational, prospective, multicenter, controlled study&#xD;
      will compare the outcomes of patients who receive reduced-intensity conditioned allogeneic&#xD;
      HSCT from a sibling or 10/10 HLA-matched unrelated donor to those of patients who receive&#xD;
      standard of care in patients with advanced-stage ETCL with poor prognostic features, will be&#xD;
      performed. Patients are included at the time of donor search irrespective of the results, and&#xD;
      compared on a donor versus no donor basis. It is an observational study since no intervention&#xD;
      is made except the comparison of outcomes of groups that receive usual care (HSCT if donor&#xD;
      available, or not).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophils Engraftment</measure>
    <time_frame>180 days</time_frame>
    <description>Neutrophils &gt; 1,000 Giga/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic graft-versus-host disease (GVHD)</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality (TRM)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Epidermotropic T-cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>HSCT</arm_group_label>
    <description>Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <description>Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HSCT</intervention_name>
    <description>Hematopoietic stem cell transplantation</description>
    <arm_group_label>HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      During the blood samples usually performed in routine patient management, 30 ml of peripheral&#xD;
      blood will be collected at inclusion and one year after inclusion and sent to the&#xD;
      investigator's central collection laboratory (INSERM UMRS 976, Saint-Louis Hospital, Paris,&#xD;
      France).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced-stage epidermotropic T-cell lymphomas (ETCL), i.e. mycosis fungoides (MF) and its&#xD;
        leukemic variant, Sézary syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 65 years&#xD;
&#xD;
          -  Histopathologically confirmed diagnosis of International Society for Cutaneous&#xD;
             Lymphomas (ISCL) / European Organisation for Research and Treatment of Cancer (EORTC)&#xD;
             stage IIB, III, IVA or IVB ETCL&#xD;
&#xD;
          -  Complete or partial response of the lymphoma (as defined by the international&#xD;
             ISCL-EORTC criteria at the time of inclusion&#xD;
&#xD;
          -  Written informed consent given by the patient&#xD;
&#xD;
          -  Contraception in women of childbearing age&#xD;
&#xD;
          -  Hematopoietic stem cell donor search underway&#xD;
&#xD;
        And at least one of the three following criteria:&#xD;
&#xD;
          -  Refractoriness or early relapse (i.e. within one year) after at least one line of&#xD;
             systemic chemotherapy (not including skin-directed therapies, methotrexate,&#xD;
             interferon-alpha, and oral retinoids)&#xD;
&#xD;
          -  Early histological large-cell transformation, i.e. within two years following ETCL&#xD;
             diagnosis&#xD;
&#xD;
          -  Histologically proven nodal (ISCL / EORTC N3) or extra-cutaneous visceral involvement&#xD;
             by the lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior allogeneic HSCT&#xD;
&#xD;
          -  Other progressive neoplastic disease&#xD;
&#xD;
          -  Progressive psychotic disease&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50% (as determined by trans-thoracic&#xD;
             echocardiography)&#xD;
&#xD;
          -  Pulmonary disease with FEV1, FVC or DLCO &lt;30% of expected corrected for hemoglobin.&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min or requiring dialysis&#xD;
&#xD;
          -  Transaminases or bilirubin &gt;two-fold the normal value in the absence of liver&#xD;
             involvement by the lymphoma&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patient with no health coverage&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  HTLV-1 lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adèle de Masson, MD</last_name>
    <phone>+33142494949</phone>
    <email>adele.de-masson@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Régis Péffault de la Tour, MD PhD</last_name>
    <phone>+33142494949</phone>
    <email>regis.peffaultdelatour@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Louis hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adèle de Masson, MD</last_name>
      <email>adele.de-masson@inserm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

